Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity
Article in Biochemical Pharmacology (September 2024)
The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.
Article in Biochemical Pharmacology (September 2024)
Article in Journal of Ethnopharmacology (August 2024)
Article in ACS Applied Materials & Interfaces (May 2024)